ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

FDA’s Handling Of UFT Raises Questions About Agency’s Isolation, Grasp Of Science.

July 21, 2000

Bennett Of NYU Heads NCI Director Search Committee

March 11, 1977

Breast Cancer Strategic Plan Underway Following HHS Secretary’s Conference

January 7, 1994

Dingell: “Unable To Vouch” For Staff Report On NCI’s Gallo

February 10, 1995

Colorectal Cancer Screening Practices Need Improvement, CDC Practice Study Finds

April 30, 2010

NCI-Approved Clinical Trials

November 24, 2006